Connect with us

Media & Technology

Relief Therapeutics Holding AG (OTC: RLFTF) Big Move as NeuroRx. (NRXP) Reports ZYESAMI™ Met Primary Endpoint in its Covid-19 Phase 2b/3 Trial

Published

on

Relief Therapeutics Holding AG (OTC: RLFTF) is making a powerful run northbound after NeuroRx reported ZYESAMI™ met the primary endpoint in its Phase 2b/3 trial* for the treatment of Respiratory Failure in critically ill patients with Covid-19. ZYESAMI™ is the first COVID-19 therapeutic to demonstrate advantages in both survival and recovery from critical COVID-19 in a randomized, double-blind multicenter trial. On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration (“FDA”) for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA).  

NeuroRx has also announced the commencement of a clinical trial of inhaled ZYESAMI™ for the treatment of patients with moderate and severe COVID-19 with the aim of preventing progression to respiratory failure. NeuroRx has announced the inclusion of inhaled ZYESAMI™ in the I-SPY clinical trial platform for patients with COVID-19 respiratory failure. The Company has signed a clinical trial participation agreement with the National Institutes of Health. ZYESAMI™ is a synthetic vasoactive intestinal peptide (VIP) and it is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. While drugs such as dexamethasone, Remdesivir and Monoclonal antibodies/convalescent plasma have been approved for fighting COVID, these drugs have minimal efficacy, are expensive to produce and difficult to transport. ZYESAMI™ is simple to manufacture and cheap to produce at scale. RLFTF has already shown investors the stock has runner in its blood when it skyrocketed to $0.95 in August after the Fox News appearance. Now that Relief is in the process of applying for for Emergency Use Authorization (EUA) as well as submitting a New Drug Application (NDA) investor may get that shot of main stream publicity that will propel RLFTF into a whole new dimension. 

Relief Therapeutics Holding AG (OTC: RLFTF) is focused on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100™ (aviptadil) is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory failure due to COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100™. Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF 

Relief’s US based partner NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on AviptadilNeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer’s Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp (NASDAQ:BRPA) (“BRPA”), and intends to apply for listing on the NASDAQ under the proposed symbol “NRXP”. 

ZYESAMI™ a synthetic vasoactive intestinal peptide (VIP), is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. VIP is shown to block Coronavirus replication in the ATII cell, block cytokine synthesis, block viral-induced cell death (cytopathy), and upregulate surfactant production. To our knowledge, other than ZYESAMI™, no currently proposed treatments for Covid-19 specifically target these vulnerable Type II cells. Recent laboratory findings suggest that VIP directly interferes with the spike protein complex of the SARS-CoV-2 virus.  

On March 29 NeuroRx reported its Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19 met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site. 

In addition to the robust overall significance across all 196 treated patients at all 10 clinical sites, the prespecified analysis of recovery from respiratory failure is clinically and statistically significant in the 127 patients treated by High Flow Nasal Cannula (HFNC) (P = .02), compared to those treated with mechanical or non-invasive ventilation at tertiary care hospitals. In this group, ZYESAMI™ patients had a 71% chance of successful recovery by day 28 vs. 48% in the placebo group (P = .017) and a 75% rate of successful recovery by day 60 vs. 55% in the placebo group (P = .036).  Eighty-four percent (84%) of HFNC patients treated at tertiary medical centers with ZYESAMI™ survived to day 60 compared with 60% of those treated with placebo (P = .007). 

https://twitter.com/KarenKEL111777/status/1375944550011789317

To Find out the inside Scoop on Relief Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RLFTF

To the company’s knowledge, ZYESAMI™ is the first COVID-19 therapeutic to demonstrate advantages in both survival and recovery from critical COVID-19 in a randomized, double-blind multicenter trial. On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration (“FDA”) for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA). 

Recovery from respiratory failure (without relapse) with discharge from acute care and survival through the observation period was the prespecified primary endpoint specified by FDA for the study, originally intended to be assessed at 28 days and then extended to 60 days based on recently-published FDA guidance. The above analysis includes all 196 participants who were randomized and treated in the placebo-controlled, double-blind clinical trial (www.clinicaltrials.gov NCT04311697) conducted at 10 US hospitals. Treatment with ZYESAMI™ or placebo was in addition to standard of care treatment that included steroids, convalescent plasma, antiviral therapy, anticoagulants, and various anti-cytokine drugs. 

NeuroRx has announced the commencement of a clinical trial of inhaled ZYESAMI™ for the treatment of patients with moderate and severe COVID-19 with the aim of preventing progression to respiratory failure. NeuroRx has also announced the inclusion of inhaled ZYESAMI™ in the I-SPY clinical trial platform for patients with COVID-19 respiratory failure. The company has signed a clinical trial participation agreement with the National Institutes of Health. 

The study’s coordinating committee, including Professors Dushyantha Jayaweera, MD, FACP (University of Miami), Richard Lee, MD, (UC Irvine), and J. Georges Youssef, MD (Houston Methodist Hospital) commented, “The 60-day observation framework implemented last month by FDA for critically ill patients with COVID-19 is more consistent with the clinical course of this lethal disease than the 28-day time frame originally adapted from other conditions that cause respiratory distress. The association of baseline oxygenation status (high flow nasal oxygen vs. ventilation) is not surprising in that patients who require mechanical or noninvasive ventilation in order to maintain blood oxygen are likely to have substantially more damage to the lining of their lungs compared to patients whose blood oxygen level can be maintained with high-flow oxygen delivered to the nose. The finding that patients fared substantially better in tertiary care centers as compared to regional hospitals may be influenced by the intensity of the public health crisis at the regional hospitals that participated in the study, all of which were operating at 200% or higher overcapacity in their intensive care units with implementation of temporary ICU beds and shortages of critical care staff.” 

Prof. Jonathan Javitt, MD, MPH, Chairman and CEO of NeuroRx, said, “ZYESAMI has now demonstrated itself in a phase 2/3 trial, conducted under FDA Fast Track Designation, not only to shorten hospitalization (as was previously reported) but also to save lives and increase the likelihood of patients returning safely home to their families. In exactly 12 months, a lifesaving drug has advanced from concept to clinical success in partnership with Relief Therapeutics in the midst of a public health emergency that has claimed the lives of millions. Today’s findings confirm the often-dramatic clinical success that has been seen in numerous patients treated in the US and abroad under emergency use protocols. We look forward to working with the National Institutes of Health, the Department of Defense, the FDA, and regulators around the world to bring this treatment to patients as quickly as possible.” 

For more on Relief Therepuetics Subscribe Right Now!

Relief Therapeutics Holding AG (OTC: RLFTF) is making a powerful run northbound after NeuroRx reported ZYESAMI™ met the primary endpoint in its Phase 2b/3 trial* for the treatment of Respiratory Failure in critically ill patients with Covid-19. ZYESAMI™ is the first COVID-19 therapeutic to demonstrate advantages in both survival and recovery from critical COVID-19 in a randomized, double-blind multicenter trial. On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration (“FDA”) for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA). NeuroRx has also announced the commencement of a clinical trial of inhaled ZYESAMI™ for the treatment of patients with moderate and severe COVID-19 with the aim of preventing progression to respiratory failure. NeuroRx has announced the inclusion of inhaled ZYESAMI™ in the I-SPY clinical trial platform for patients with COVID-19 respiratory failure. The Company has signed a clinical trial participation agreement with the National Institutes of Health. ZYESAMI™ is a synthetic vasoactive intestinal peptide (VIP) and it is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. While drugs such as dexamethasone, Remdesivir and Monoclonal antibodies/convalescent plasma have been approved for fighting COVID, these drugs have minimal efficacy, are expensive to produce and difficult to transport. ZYESAMI™ is simple to manufacture and cheap to produce at scale. RLFTF has already shown investors the stock has runner in its blood when it skyrocketed to $0.95 in August after the Fox News appearance. Now that Relief is in the process of applying for for Emergency Use Authorization (EUA) as well as submitting a New Drug Application (NDA) investor may get that shot of main stream publicity that will propel RLFTF into a whole new trading range. We will be updating on Relief on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Relief.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in Relief either long or short and we have not been compensated for this article.

Featured

Creatd, Inc. (OTCMKTS: CRTD) Stock Price Continues to Deteriorate as the Legal Battle with The Lind Partners, LLC Continues

Published

on

Creatd, Inc. (OTCMKTS: CRTD) share value continues to drop after a brief recovery in mid-March. The firm’s stock is still not at the lowest point it has ever been, but it is not too far off at this point. The lowest that the shares have gone was $0.0457, which is the point they reached on October 11th, 2022. After that, in the final months of the previous year, the stock price shot up, reaching $1.6941 per share on November 18th.

The last time when the shares reached this height was in February 2022. However, back then, the price was rapidly spiraling down from a much higher point. Unfortunately for the company and its investors, after reaching $1.6941 in November, the share price crashed in a sharp correction, sinking to $0.50 by the end of November.

CRTD found a strong support at this level, which allowed it to bounce back up to $0.90, which is where the company encountered a strong resistance. It kept bouncing back and forth between these two levels throughout December 2022 and January 2023. However, as time passed, the fluctuations were becoming smaller, as the price seemingly started achieving greater stability. Looking back now, however, it becomes clear that the volatility may have decreased, but the overall trend became bearish somewhere in mid-January.

To Find out the inside Scoop on CRTD, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

CRTD price was dropping again, and in the second half of February, it broke the support level at $0.50, sinking to $0.16 by February 27th. After briefly recovering in early March, the price went back up to $0.3, encountering a resistance here, as well, which pushed it back down to $0.1156 this time, which was on March 14th. In the last 48 hours, the price managed to recover a bit once more, sitting at $0.15 at the time of writing.

Creatd, Inc. (OTCMKTS CRTD) stock price continues to deteriorate as the legal battle with The Lind Partners, LLC continues

Creatd, Inc. (OTCMKTS: CRTD) stock has seen a rough performance over the last year, with only a brief period of recovery in November 2022. Other than that, the last 12 months were marked by nothing but price crashes triggered by various events that followed the company. In recent months — specifically in December — the company announced an upcoming merge with Global Tech Industries, albeit without disclosing the terms of the deal. After that, reports said that Global Tech Industries had decided to bid $100 million in stock in order to acquire Creatd. Creatd even halted any discussions with other potential acquirers for 30 days as part of the LOI. At the time, its CEO and Chairman, Jeremy Frommer, said:

There are two elements to this merger, fundamental and technical. The opportunity to advance the Creatd business model and scale revenues coupled with the unique technical position we find our two public companies in, is a momentous opportunity. At the time of closing of any proposed transaction, GTII share delivery to Creatd shareholders will only occur in instances of registered ownership with the transfer agent or DTC.

For a time, everything was going well for the company until February 24th, when reports emerged that Creatd had terminated the proposed acquisition discussions with Global Tech. This was what triggered the stock crash, as many were disappointed that the deal did not succeed.

Around that time, the company was also struggling with a potential illegal naked short selling, and it launched CEOBLOC to try and fight it. One positive development at the time was the fact that CRTD became available on Upstream, which marked the third issuer to dual-list their shares on Upstream’s blockchain-powered market.

https://twitter.com/UpstreamXchange/status/1625520006770618368

However, the stock was hit with another blow a week ago when Creatd released an update regarding its legal dispute with The Lind Partners, LLC, and the company’s affiliates. The dispute concerns a convertible promissory note that amounts to $900,000.

For more on CRTD Subscribe Right Now!

According to Lind, Creatd breached certain representations and warranties in regard to the note. Lind demanded immediate repayment of the full amount, but Creatd instead decided to offer a number of alternatives. Lind refused to negotiate and Creatd filed a motion to dismiss. The company’s CEO said:

At this early stage, we are strictly trying to analyze data. There is more than enough evidence that there has been unusual trading in CRTD and it demands further investigation. To that end, we have asked legal counsel to look into filing multiple requests of trading records from market makers in CRTD stock. When and if the Company enters the discovery period in The Lind Partners, LLC case, any trading records related to The Lind Partners, LLC that were done with external broker dealers will also be analyzed.

Creatd, Inc. (OTCMKTS: CRTD) is a holding company that offers new economic opportunities to creators using partnerships and technology. The company’s goal is to empower creators and brands, and it claims that each of its companies shares a common mission — to create technologies and develop partnerships that would allow it to unlock new opportunities useful to entrepreneurs, brands, and creators, allowing them to also grow creatively, sustainably, as well as profitably.

For the moment, it appears that the situation is not the best for the company. It is in the middle of legal proceedings, its merger has failed, and its stock is one bad day away from reaching its all-time low. The chart above shows that CRTD is willing to grow and ready to jump on any opportunity, so the company still has a chance. Any piece of good news would likely send its stock to the path of recovery, which is why it is still worth keeping an eye on future developments. We will be updating on CRTD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CRTD.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sang Hyun Cho from Pixabay

Continue Reading

Featured

Global Developments Holdings, Inc (OTCMKTS: GDVM) Share Starts Recovery After a Second Big Drop in Three Months

Published

on

Global Developments Holdings Inc (OTCMKTS: GDVM) share has steadily risen for the past six and a half months. The company’s performance in 2023 has been remarkable.

Global Developments Holdings Inc (OTCMKTS: GDVM) share has been on a steady rise for the past six and a half months. The company’s performance in 2023 shows that the share was growing, then it saw a sudden surge, only to crash back down. However, the company’s 6M chart clearly indicates that the share has been rising steadily, and both rapid surges followed by sudden crashes — one in November/December 2022 and another in February 2023 — were only brief pumps. The stock’s performance overall still indicates that GDVM is seeing a strong, steady rise, which was not affected by these instances of strong volatility.

The GDVM price was fairly stable for the first eight months of 2022, slightly fluctuating around $0.0040. However, at the end of August 2022, the price started to grow. The growth was steady, healthy, and the price kept going up, almost completely uninterrupted until November 3rd. At the time, it reached $0.0527, but after reaching this level, it saw a slight correction to a support at $0.040. After only about a week at this level, a rapid surge took it all the way up to $0.1109. The surge started around November 16th, and it reached its peak by December 6th.

After that, a rapid correction made the price crash back down to $0.056 later on the same day. After an attempt at recovery, the price dropped again on December 14th, this time sinking to $0.038. From there on, the price managed to return back to its steady growth, which actually lasted until late January 2023. At the time, it reached $0.066, when another surge took place, starting on January 27th.

To Find out the inside Scoop on GDVM, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In the following month, the price climbed up to $0.1359, reaching this height on February 23rd, which was once again followed by a rapid crash back to $0.0726. What followed was a few weeks of stability, which led the price to finally grow back up again, to $0.0862, on March 9th. This was followed by another mild correction to $0.769, which is where the GDVM price sits right now at the time of writing.

Global Developments Holdings, Inc (OTCMKTS GDVM) Share Starts Recovery After a Second Big Drop in Three Months

Global Developments Holdings, Inc (OTCMKTS: GDVM) price behavior has been quite significant over the last six months. However, it is also worth noting that most of these developments — the beginning of the six-month steady growth, as well as rapid price surges in between — took place when some major developments for the company happened. For example, the price started climbing up in August after reports that it reduced OS by 525 million, with rumors that significant moves are being made behind the scenes. At the time, it was rumored that the company was planning a reverse merger, which is exactly what it was doing, as it was discovered later on.

Following that, reports in November emerged, noting that the reverse merger is heating up, especially as the new CEO was affected by massive share reduction. The merger was with a company VeeMost, and by early December 2022, it achieved its 4th advanced specialization. At the time, reports were also praising GDVM as its stock price continued to skyrocket. The stock has been under heavy accumulation from the moment Mr. Melvin Ejiogu, an executive who also acts as President of VeeMost Technologies, became the controlling shareholder. He said:

$GDVM majority control acquired and all outstanding debt purchased. I also purchased 12% of outstanding shares and returned them to the treasury. No dilution will occur. I’ll be sharing updates soon with everyone on our new journey.

His new dilution policy affected a massive share reduction, as mentioned, and trapped the market makers, who were seriously short. The reverse merger stocks have proven that they can be much more explosive than biotechs, assuming that the incoming company has real value. By mid-February, Global Developments became the highest overall rated company in the Shell Companies industry. It had an overall score of 66 while and an average score of 43. This means that, on average, the stock in this industry tends to score higher than 43% of the stock market. However, according to Ejiogu’s tweet published on February 17th, he was working on getting the shell status removed from GDVM.

Global Developments Holdings, Inc (OTCMKTS: GDVM) is a company that provides expert consulting for businesses. It is a principal investment firm that specializes in acquisitions and early-stage financing of emerging growth companies. It describes its service as fast and reliable, and it can help whether its clients need help with finances, advice on theoretical matters, or assistance with practical tasks.

For more on GDVM Subscribe Right Now!

It has a highly-qualified team that is happy to assist with any needs in both private and commercial spheres. The company is based in Delaware, and it was incorporated on December 9th, 2004, as Autobahn International, Inc. However, in 2016, it rebranded to Global Developments Inc and then once more to Global Developments Holdings, Inc, on September 20th, 2018.

For the time being, the company’s stock is still growing steadily after starting to increase in August of last year. The past price surges, followed by sharp corrections, are fairly normal behavior. Prices tend to surge after beneficial developments, and a sharp rise is always followed by a sharp correction. The positive thing is that the price continues to increase after the correction is over, and the chart above clearly shows that the company continues to thrive under the new leadership. We will be updating on GDVM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GDVM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have no position in GDVM and have not been compensated for this article.

Image by David Mark from Pixabay

Continue Reading

Featured

Asia Broadband, Inc (OTCMKTS: AABB) Stock Price Surges as the Firm Takes a Stance Against Market Maker Manipulation Practices

Published

on

Asia Broadband, Inc. (OTCMKTS: AABB)

Asia Broadband, Inc. (OTCMKTS: AABB) saw its stock price surge by over 10% in the last 24 hours following its decision to pursue market manipulation legal action against some major market makers. The firm’s stock price surged from $0.0290 to the current $0.0334, which was also the closing price on Thursday, March 9th. Before this, the firm’s price has had several spikes up over the last six months, although each of them was too sharp to last, and they were always followed by just as strong corrections. The last big example came around February 21st, with January 31st before that and January 17th before that.

To Find out the inside Scoop on AABB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The situation was slightly different in late 2022 when Asia Broadband saw a strong price surge around November 23rd, which led it to the high point of $0.0559 by December 6th. The following correction took the price back down to an average level of $0.033, with the price fluctuating around it until early February 2023. After that, the price sank to the support at $0.030, and it just broke it in the early days of March, going down to $0.028 before surging back up over the last two days.

Over the past six months or so, each of the strong price reactions that AABB has displayed took place roughly around the same time as some important events for the company. For example, in December 2022, the company launched the GoldenBaboons.com website in preparation for the launch of its Gold-Backed NFT Baboons collection, which went live in January. The collection Golden Baboons Mining Club (GBMC) was the first NFT collection that AABB has created and published. Furthermore, it is backed by gold, like the company’s AABBG token.

Another time the price had reacted was in January of this year, right after the reports of Asia Broadband completing a plant site purchase to process gold and silver ore. The firm announced the purchase of the new processing facility, and an evaluation report has estimated the stockpile to represent more than $800 million in gold and silver. Reports at the time have called the stockpile processing project the largest high-yield asset addition for the firm to date, and it was considered a part of its strategic expansion initiative, meant to help the Company acquire gold production and increase AABB’s physical gold holdings. Then, only about a week after that, new reports said that Asia Broadband is continuing its strategic expansion of its Central America cryptocurrency operations hub in El Salvador — specifically, in its Bitcoin City.

Finally, in mid-February, the company announced a registration deadline to purchase its gold-backed Baboons NFT collection during the NFT mint event. The deadline was February 22nd, and the minting took place after that, on February 28th. As for this latest AABB price surge, it came around the time when another new report emerged, stating that Asia Broadband pursues market manipulation legal action against major market makers for AABB shares on OTC Markets.

The legal initiative has actually progressed for months, as the company noted that many shareholders and public firms received expressing that the AABB share price was subjected to long-term repression by deceptive and false trading practices. Furthermore, other OTC Market issuers were already publicly exposed and legally challenged due to their market maker manipulation practices. Apart from that, Asia Broadband is also pursuing legal action against a number of parties for multiple defamatory internet posts.

The Company experienced similar defamation attacks several years ago, and the situation was resolved to the firm’s advantage, with the posts permanently removed. The company’s CEO and AABB President, Chris Torres, said:

We have an obligation to our shareholders to do everything in our power to protect their investments in our Company’s shares. Our share price is not reflecting the true value attributed to the Company’s successes in recent years due to deceitful and profiteering market manipulation.

While the name, Asia Broadband, Inc. (OTCMKTS: AABB), suggests that this is a telecommunications firm, AABB is actually a mining stock. Operating as a resource company with a special focus on the production, supply, and sale of precious and base metals, Asia Broadband primarily sells to Asian markets.

The firm uses specific geographic expertise, coupled with extensive industry contacts and a long and rich experience to facilitate innovative distribution processes from the production and supply of base and precious metals in Mexico to its clients, which can be found all over Asia. With that said, the company’s most prominent move as of late has been an attempt to develop a gold-backed cryptocurrency token and a gold-backed NFT collection mentioned earlier. The token itself is known as AABBG, and it was backed by $30 million in gold holdings as of 2021 when it was originally released.

For more on AABB Subscribe Right Now!

Despite the relatively poor stock price performance, Asia Broadband, Inc (OTCMKTS: AABB) is a mining firm that has great potential for the future. Its involvement with crypto assets and the fact that it supplies Asian clients both work in its favor. Asia is emerging as one of the leading regions in terms of technology and digital assets. With the company operating in the West on behalf of the East, it is in a perfect position to grow. Furthermore, if allegations of defamation and market manipulations from its lawsuit turn out to be true, that would explain the difficulties in AABB’s performance that the company has been facing, which could allow its stock to start growing once these negative aspects get removed. We will be updating on AABB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with AABB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in AABB, either long or short, and we have not been compensated for this article

Image by Tom und Nicki Löschner from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.